Success Metrics

Clinical Success Rate
55.6%

Based on 5 completed trials

Completion Rate
56%(5/9)
Active Trials
1(6%)
Results Posted
20%(1 trials)
Terminated
4(25%)

Phase Distribution

Ph phase_4
4
25%
Ph not_applicable
1
6%
Ph phase_2
3
19%
Ph phase_1
1
6%
Ph phase_3
7
44%

Phase Distribution

1

Early Stage

3

Mid Stage

11

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
3(18.8%)
Phase 3Large-scale testing
7(43.8%)
Phase 4Post-market surveillance
4(25.0%)
N/ANon-phased studies
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

45.5%

5 of 11 finished

Non-Completion Rate

54.5%

6 ended early

Currently Active

1

trials recruiting

Total Trials

16

all time

Status Distribution
Active(2)
Completed(5)
Terminated(6)
Other(3)

Detailed Status

Completed5
Terminated4
unknown3
Withdrawn2
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
1
Success Rate
55.6%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (6.3%)
Phase 23 (18.8%)
Phase 37 (43.8%)
Phase 44 (25.0%)
N/A1 (6.3%)

Trials by Status

withdrawn213%
completed531%
unknown319%
terminated425%
enrolling_by_invitation16%
recruiting16%

Recent Activity

1 active trials
Showing 5 of 16
terminatedphase_4

Endothelial Protection in Convalescent COVID-19 Patients

NCT05252923
enrolling_by_invitationphase_3

Sulodexide in Controlling the Recurrence of Psoriasis

NCT06982196
completedphase_3

Endothelial Protection in Post COVID-19 Patients With Sulodexide

NCT05371925
recruitingphase_3

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

NCT04257487
unknownnot_applicable

The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

NCT05654233
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT05252923Phase 4

Endothelial Protection in Convalescent COVID-19 Patients

Terminated
NCT06982196Phase 3

Sulodexide in Controlling the Recurrence of Psoriasis

Enrolling By Invitation
NCT05371925Phase 3

Endothelial Protection in Post COVID-19 Patients With Sulodexide

Completed
NCT04257487Phase 3

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

Recruiting
NCT05654233Not Applicable

The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

Unknown
NCT00130312Phase 4

Effect of Sulodexide in Overt Diabetic Nephropathy

Terminated
NCT04483830Phase 2

Suloexide in the Treatment of Early Stages of COVID-19

Completed
NCT03370705Phase 3

Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone

Unknown
NCT03504566Phase 4

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Withdrawn
NCT00130208Phase 3

Effect of Sulodexide in Early Diabetic Nephropathy

Completed
NCT02737670Phase 2

Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus

Completed
NCT02512601Phase 4

Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide

Terminated
NCT00462202Phase 3

Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

Terminated
NCT00583427Phase 1

Sulodexide Treatment in Patients With Dense Deposit Disease

Withdrawn
NCT01295775Phase 2

Diabetic Retinopathy Sulodexide Study

Completed
NCT01000545Phase 3

The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease

Unknown

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16